Company Overview
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is a phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, an HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was headquartered in Bothell, Washington.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -69.3%.
- 5-Year Trend Long-term compounding — revenue CAGR -60.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -60.20% |
| 1 Year: | -69.32% |
Stock Price Performance
| 1 Year: | -29.76% |
| 6 Months: | +14.56% |
| 3 Months: | +16.83% |
| 1 Month: | +11.32% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)60.47 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -60.2% CAGR over 5 years.
- Trading 30.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | COCP Cocrystal Pharma, Inc. PHARMA | 1.18 | -1.57 | $22.73M | 0.00% | -120.22% | - | -60.20% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.08M | 592.00K | 492.00K | 461.00K | 554.00K | 489.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -1.53M | -1.39M | -1.22M | -2.17M | -3.82M | -3.59M | -44.37M | -5.33M | -4.20M | -1.89M | -94.39M | -3.12M | -2.11M | -2.11M | -1.83M | -2.07M | -2.13M | -2.42M | 2.88M | -1.55M | -1.81M | -1.96M | -3.45M | -2.71M | -2.74M | -3.83M | -3.95M | -4.21M | -24.43M | -5.69M | -5.11M | -4.34M | -4.44M | -4.16M | -5.45M | -5.04M | -2.34M | -2.11M | -2.09M | -2.36M |
| Net Income | -372.00K | 4.73M | -2.55M | -16.54M | -2.62M | -508.00K | -30.45M | -4.01M | -3.23M | -1.88M | -65.75M | -2.55M | -2.26M | -1.96M | 4.90M | -1.55M | -1.34M | -1.87M | 2.97M | -1.51M | -1.78M | -1.99M | -3.50M | -2.67M | -2.74M | -3.82M | -3.94M | -4.21M | -24.43M | -5.70M | -5.19M | -4.17M | -4.17M | -3.96M | -5.34M | -4.94M | -2.30M | -2.06M | -2.05M | -2.30M |
| Diluted EPS | 0.00 | 0.01 | -0.01 | -0.04 | -0.01 | -0.01 | -0.05 | -0.17 | -0.14 | -0.03 | -3.06 | -0.11 | -0.09 | -0.08 | 0.20 | -0.06 | -0.05 | -0.06 | 0.10 | - | - | -0.05 | - | - | -0.04 | - | - | - | -3.00 | -0.70 | -0.64 | -0.41 | -0.41 | -0.39 | -0.53 | -0.49 | -0.23 | -0.20 | -0.19 | -0.17 |
| R&D Expense | 967.00K | 888.00K | 866.00K | 1.56M | 1.95M | 2.18M | 38.70M | 3.34M | 2.37M | 2.09M | 93.88M | 2.07M | 1.39M | 1.39M | 1.10M | 877.00K | 1.12M | 1.47M | 878.00K | 1.09M | 1.08M | 1.28M | 1.98M | 2.08M | 1.58M | 2.56M | 2.10M | 2.87M | 2.36M | 3.87M | 3.91M | 2.80M | 4.19M | 2.95M | 4.31M | 3.24M | 1.36M | 1.12M | 954.00K | 1.37M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 12.71M | - | - | - | - | - | - | - | 6.56M | 2.01M | - | - | - | - | - |
| Gross Profit | 6.83M | 2.69M | 7.22M | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -32.05K | -3.89M | -2.55M | -4.08M | -5.80M | -53.95M | -105.82M | -8.26M | -62.92M | -48.41M | -9.59M | -14.22M | -38.83M | -18.56M | -17.88M | -9.02M |
| Net Income | -319.81K | -5.46M | -7.96M | -3.89M | -99.00K | -50.12M | -74.87M | -613.00K | -49.05M | -48.17M | -9.65M | -14.19M | -38.84M | -17.98M | -17.50M | -8.83M |
| Diluted EPS | - | - | - | -0.07 | -0.01 | -2.40 | -3.30 | -0.03 | - | - | - | - | -4.77 | -1.87 | -1.72 | -0.78 |
| R&D Expense | 240.87K | 423.18K | 489.35K | 3.86M | 4.07M | 47.26M | 101.68M | 5.82M | 4.67M | 4.00M | 6.03M | 8.79M | 12.39M | 15.17M | 12.54M | 5.05M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 7.53M | 7.55M | 7.24M | 1.66M | 259.28M | 224.23M | 124.88M | 121.43M | 68.56M | 28.53M | 54.24M | 79.39M | 40.84M | 31.26M | 13.46M | 9.71M |
| Total Equity | -226.36K | -589.20K | -2.77M | -5.01M | -8.83M | 6.65M | 167.59M | 102.32M | 105.40M | 66.89M | 25.71M | 52.51M | 77.55M | 39.60M | 26.38M | 9.52M | 6.33M |
| Cash & Equivalents | 587.41K | 251.47K | 35.37K | 4.72M | 1.03M | 3.97M | 9.28M | 3.60M | 748.00K | - | 7.42M | 33.01M | 58.70M | 37.14M | 26.35M | 9.86M | 7.03M |
| Long Term Debt | - | - | - | - | - | 65.26M | 49.94M | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | 386.00K | 74.41M | 56.64M | 22.56M | 16.03M | 1.67M | 2.82M | 1.74M | 1.84M | 1.27M | 4.88M | 3.93M | 3.38M |
| Current Liabilities | - | 5.08M | 7.28M | 10.82M | 386.00K | 9.16M | 6.70M | 2.04M | 1.44M | 1.56M | 2.29M | 1.36M | 1.54M | 1.22M | 3.26M | 2.43M | 2.21M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | -1.59M | -3.69M | -6.01M | -10.32M | -14.65M | -6.90M | -8.29M | -1.56M | -9.83M | -12.72M | -21.43M | -14.67M | -16.48M | -8.19M |
| Investing Cash Flow | -357.61K | 10.29K | -152.13K | -4.00K | 6.08M | -262.00K | 3.00K | -40.00K | 1.37M | -145.00K | -240.00K | -52.00K | -74.00K | -118.00K | -8.00K | -12.00K |
| Financing Cash Flow | 283.10K | 575.52K | 1.71M | 7.00K | 2.87M | 15.88M | 9.02M | 4.08M | 8.89M | 6.42M | 35.66M | 38.47M | -27.00K | 3.99M | - | 5.37M |
| Capital Expenditure | -357.61K | -575.43K | -152.13K | -4.00K | -5.00K | -339.00K | -51.00K | -40.00K | -28.00K | -145.00K | -240.00K | -52.00K | -74.00K | -118.00K | -8.00K | -12.00K |
| Free Cash Flow | - | - | -1.74M | -3.69M | -6.02M | -10.66M | -14.71M | -6.94M | -8.32M | -1.71M | -10.07M | -12.77M | -21.51M | -14.78M | -16.49M | -8.20M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | 21.1% | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | -30.6% | - | - | - | - | - | - | - | -737.4% | -476.0% | - | - | - | - | - |
| Net Margin % | - | -42.9% | - | - | - | - | - | - | - | -733.8% | -479.0% | - | - | - | - | - |
| ROE % | 54.3% | 197.1% | 159.0% | 44.0% | -1.5% | -29.9% | -73.2% | -0.6% | -73.3% | -187.4% | -18.4% | -18.3% | -98.1% | -68.2% | -183.8% | -139.5% |
| ROCE % | -1.3% | -1,447.9% | 71.3% | -320.1% | -2.3% | -24.8% | -86.1% | -6.9% | -93.9% | -184.4% | -18.1% | -18.3% | -98.0% | -66.3% | -162.1% | -120.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 1.86% | 358.23K | $433.45K |
| 2 | Renaissance Technologies, LLC | 0.93% | 179.63K | $217.35K |
| 3 | Two Sigma Investments, LP | 0.91% | 175.38K | $212.21K |
| 4 | Geode Capital Management, LLC | 0.40% | 76.21K | $92.21K |
| 5 | Blackrock Inc. | 0.38% | 73.75K | $89.23K |
| 6 | Citadel Advisors Llc | 0.23% | 45.12K | $54.59K |
| 7 | Neuberger Berman Group, LLC | 0.17% | 31.89K | $38.58K |
| 8 | Xtx Topco Ltd | 0.15% | 29.34K | $35.50K |
| 9 | Jane Street Group, LLC | 0.13% | 25.76K | $31.17K |
| 10 | Vanguard Fiduciary Trust Co | 0.12% | 24.02K | $29.06K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for COCP
We're Keeping An Eye On Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNV3ZXYmpPT1FnVFlyWENFLXdCdFVhUHljOTB3dUNxYlRXTEZ5aGZnZFhzOUVtb09vY0w1SUhUdy1FYkM5bHh1d2p4WnNadlh6MVpXREh0Qzdid1hUdVdMWlVmOGItNGZsVm1uTGM5S2hlVXJISUlDMGwtUnV1ZE1abnNTMlVkR2JfNkpGcF…
COCP Stock Soars 75% — What Is The Link To Cocrystal’s Norovirus Treatment? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxNb2h6OGJndjFid3dfVk53R3pIdVNrWWltaGU3RDk4ZHduVzh1dWh0eEdXSllnemVXTmM3dFJVcnRIN1BMR2tCelJxVGJlSWVGUzBnWlJJWldDYVdLYUR6bHNpWm9Ockk1YV9XZjd5eFZJeFNlUjhjVmdmVGpvZHdGX3JrYUMzWnd4dG1CMl…
A Gilead veteran joins Cocrystal’s board to guide antiviral drug development - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxPNENnRVE2MzFJMHdtdWN0UVAwWkExLXlyc3o3MEdNWGFiTGFlQXZ2dzQxWjEwV2dGNENkaWFaNHdOS0R1aEZUdnFMcG0tU1NEaWY3U2R4UE10dmhEaC05YWhXTVAwNG5SaGlWMUxqSlF4QVBFUHNYUDRUalh5VVZnbW0ycEFPa3E3UjhWQk…
COCP - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9vcXNPQjYySnh0aWhmOS13NUJUclZZckF4elBoS3dRdWlsWWlEUURXUXNaZVpzR3M4Rkk1UXlIQnl4cDJmMGc?oc=5" target="_blank">COCP</a> <font color="#6f6f6f">Finviz</font>…
Cocrystal Pharma (COCP) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España
<a href="https://news.google.com/rss/articles/CBMiU0FVX3lxTE05QUVEbHhsMWdqVlpTRVJCNl9pOFZ0RHBPZnRHR2pzblNFMUU4dXRSVVVwQ2xtMFNhMHdzTndTcGZlNElpaDFQRDRLZmVmZkt0WlFN?oc=5" target="_blank">Cocrystal Pharma (COCP) Stock Analysis Report | Ratings…
We're Keeping An Eye On Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxNeVRLYVdWN1p5eVNnNTZSUEhPY0ZhV25TT1RwR0hDUkpTQWJ1QVZTV1IxOGpqWnJlTUNWZVJMckZ1ZG94TkZRaC1mLUlQSHVKbDBDUndwVnlhd3ZSZ1BXWVJMNjlkV3VnUU95aHpiNklibWFDN0pzTFFMNjlPSFNoQ01BOERXSlhsMkRZQ3…
COCP — Frequently Asked Questions
What is the current share price of Cocrystal Pharma, Inc. (COCP)?
As of 2026-09-19 21:16 PDT, Cocrystal Pharma, Inc. (COCP) trades at $1.18 on NasdaqCM. Its 52-week range is $0.82 to $1.70.
What is the market capitalisation of COCP?
Cocrystal Pharma, Inc. (COCP) has a market capitalisation of $22.73M on NasdaqCM.
What is the P/E ratio of COCP?
COCP trades at a trailing price-to-earnings (P/E) ratio of -1.57. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 16.32.
Is COCP a good stock to buy?
This page provides a data-driven analysis of Cocrystal Pharma, Inc. (COCP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.